b
r
c
sarscov
caus
global
pandem
infect
peopl
month
vaccin
sar
still
avail
develop
novel
method
produc
high
level
recombin
sar
viruslik
particl
vlp
vaccin
contain
sar
spike
protein
influenza
protein
use
baculoviru
insect
cell
express
system
chimer
sar
vlp
similar
size
morpholog
wild
type
sarscov
test
immunogen
protect
efficaci
purifi
chimer
sar
vlp
full
length
sar
protein
vaccin
mous
lethal
challeng
model
sar
vlp
vaccin
contain
g
sar
protein
complet
protect
mice
death
administ
intramuscular
im
intranas
rout
absenc
adjuv
likewis
sar
vlp
vaccin
contain
g
protein
without
adjuv
reduc
lung
viru
titer
detect
level
protect
mice
weight
loss
elicit
high
level
neutral
antibodi
sarscov
cellproduc
full
length
purifi
sar
protein
also
effect
vaccin
sarscov
coadminist
im
aluminum
hydroxid
sarscov
vlp
highli
immunogen
induc
neutral
antibodi
provid
protect
lethal
challeng
cellbas
vlp
vaccin
potenti
tool
provid
protect
novel
pandem
agent
sever
acut
respiratori
syndrom
sar
emerg
infecti
diseas
novemb
juli
sar
global
outbreak
spread
guang
dong
provinc
china
southeast
asia
north
america
world
health
organ
report
total
sar
case
countri
juli
includ
death
mortal
rate
wave
sar
pandem
final
contain
intern
coordin
strict
quarantin
enforc
local
govern
addit
loss
life
affect
region
suffer
signific
social
disrupt
econom
turmoil
sar
caus
flu
like
symptom
includ
high
fever
cough
difficulti
breath
pneumonia
spread
person
person
close
contact
via
respiratori
droplet
cough
sneez
specif
antisar
treatment
vaccin
avail
sar
caus
newli
identifi
viru
sarsassoci
coronaviru
sarscov
sarscov
nm
diamet
envelop
singl
strand
rna
viru
contain
kb
genom
open
read
frame
sarscov
four
major
structur
protein
spike
membran
envelop
e
nucleocapsid
n
protein
protein
type
transmembran
glycoprotein
respons
viru
bind
viru
penetr
major
induc
neutral
antibodi
cellular
immun
protein
main
target
antigen
sar
vaccin
develop
although
interepidem
period
report
sar
case
worldwid
safe
effect
sar
vaccin
remain
import
public
health
need
natur
reservoir
sarslik
coronaviru
wild
bat
palm
civet
human
could
infect
close
contact
unknown
wild
anim
reservoir
also
report
case
laboratori
acquir
sar
viru
infect
research
sarscov
classifi
nation
institut
allergi
infecti
diseas
biodefens
categori
c
prioriti
pathogen
potenti
use
biolog
weapon
current
approv
sar
vaccin
limit
human
clinic
trial
candid
vaccin
done
previou
sar
vaccin
develop
fall
sever
categori
inactiv
sarscov
base
vaccin
dna
recombin
virus
express
spike
glycoprotein
subunit
vaccin
contain
receptor
bind
domain
solubl
ectodomain
viru
like
particl
vlp
base
vaccin
sarscov
vlp
vaccin
candid
shown
consider
promis
recombin
vlp
vaccin
develop
drawn
increas
attent
potenti
safer
inactiv
attenu
viral
vaccin
immunogen
subunit
dna
vaccin
recent
recombin
influenza
vlp
vaccin
report
well
toler
immunogen
human
trial
sar
protein
incorpor
vlp
compos
either
e
n
structur
protein
shown
produc
low
level
mammalian
cell
baculoviru
insect
cell
express
system
sar
protein
incorpor
secret
intracellular
vlp
compos
sar
e
low
yield
effort
address
low
yield
sarscov
vlp
chimer
vlp
contain
sarscov
e
n
mous
hepat
viru
produc
show
increas
yield
rel
wild
type
vlp
express
mammalian
cell
addit
immun
vlp
reduc
lung
viru
titer
mous
challeng
model
although
sar
vlp
format
immunogen
shown
promis
studi
express
level
remain
less
would
need
viabl
commerci
vaccin
candid
report
describ
novel
method
produc
high
level
sar
vlp
insect
cell
infect
recombin
baculoviru
contain
chimer
sarscov
protein
contain
influenza
hemagglutinin
ha
transmembran
carboxyl
terminu
avian
influenza
matrix
protein
chimer
sar
vlp
effici
produc
secret
infect
insect
cell
purifi
chimer
sar
vlp
shown
complet
protect
immun
mice
lethal
challeng
sarscov
immun
recombin
purifi
sar
protein
alon
produc
partial
protect
amino
acid
sequenc
sarscov
urbani
strain
spike
protein
influenza
hemagglutinin
ha
matrix
protein
obtain
ncbi
protein
databas
construct
chimer
sar
protein
transmembran
carboxyl
terminu
tmct
sar
protein
aa
remov
replac
tmct
ha
aa
codon
optim
dna
sequenc
sar
protein
chimer
protein
protein
use
high
level
express
insect
cell
biochem
synthes
geneart
ag
regensburg
germani
code
sequenc
individu
clone
bamhi
hindiii
site
baculoviru
transfer
vector
plasmid
invitrogen
carlsbad
ca
digest
snabi
pvui
bp
fragment
contain
code
sequenc
gel
purifi
digest
hpai
pvui
bp
fragment
contain
code
sequenc
gel
purifi
bp
bp
fragment
ligat
togeth
dna
ligas
roch
indianapoli
process
produc
tandem
plasmid
contain
chimer
sar
gene
gene
gene
control
polyhedrin
promot
tandem
chimer
wild
type
full
length
sar
transfer
vector
transform
compet
cell
invitrogen
produc
bacmid
bacmid
transfect
spodoptera
frugiperda
insect
cell
atcc
gener
recombin
baculoviru
use
bactobac
baculoviru
express
system
invitrogen
cell
maintain
suspens
hyqsfx
insect
serum
free
medium
hyclon
logan
ut
c
cell
infect
cellsml
cell
densiti
h
recombin
baculoviru
encod
sar
chimer
vlp
protein
multipl
infect
moi
sar
protein
exact
infect
cell
pellet
nonion
deterg
tergitol
sigmaaldrich
st
loui
mo
clarifi
supernat
deterg
extract
purifi
fractogel
tmae
anion
exchang
captur
column
emd
chemic
darmstadt
germani
follow
lentil
lectin
sepharos
affin
column
ge
healthcar
piscataway
nj
final
polish
sephacryl
size
exclus
column
ge
healthcar
chimer
sar
vlp
refer
vlp
later
text
purifi
infect
cell
cultur
medium
tangenti
filtrat
anion
exchang
size
exclus
chromatographi
procedur
report
influenza
vlp
purif
purifi
protein
chimer
vlp
analyz
sdspage
bistri
nupag
invitrogen
stain
gelcod
blue
stain
pierc
rockford
il
quantifi
scan
densitometri
use
onedscan
softwar
bd
bioscienc
rockvil
md
anim
studi
purifi
protein
chimer
vlp
normal
amount
sar
protein
concentr
base
total
protein
bca
assay
pierc
protein
content
puriti
densitometri
ident
sar
protein
influenza
protein
confirm
western
blot
use
follow
antibodi
rabbit
antisar
antibodi
imgnex
san
diego
ca
mous
antiinfluenza
antibodi
abd
serotec
oxford
uk
goat
antimous
goat
antirabbit
phosphatas
label
secondari
antibodi
kpl
gaithersburg
md
bcipnbt
phosphatas
substrat
kpl
use
develop
western
blot
particl
size
sar
protein
vlp
vaccin
measur
dynam
light
scatter
use
zetas
nano
malvern
instrument
worcestershir
uk
chimer
sar
vlp
adsorb
min
flotat
onto
freshli
discharg
mesh
carbon
parlodionco
copper
grid
polysci
warrington
pa
grid
rins
mm
tri
ph
mm
kcl
neg
stain
phosphotungst
acid
dri
aspir
vlp
visual
hitachi
transmiss
electron
microscop
hitachi
high
technolog
america
schaumburg
il
oper
kv
digit
captur
ccd
camera
resolut
advanc
microscopi
techniqu
corp
danver
immunoelectron
microscopi
immuno
em
rabbit
antisar
antibodi
imgnex
use
primari
antibodi
nm
colloid
goldaffin
pure
goat
antirabbit
igg
jackson
immuno
research
west
grove
pa
use
secondari
antibodi
describ
previous
total
group
week
old
femal
balbc
mice
anim
per
group
use
studi
nine
group
vaccin
intramuscularli
im
hind
limb
vehicl
pb
g
g
sar
vlp
vaccin
without
aluminum
hydroxid
brenntag
ag
germani
adjuv
five
group
vaccin
intranas
vehicl
g
g
sar
vlp
vaccin
without
adjuv
anim
vac
cinat
day
day
day
mice
intranas
challeng
lethal
dose
ld
mouseadapt
sarscov
strain
ld
tcid
day
day
post
challeng
mice
group
sacrif
collect
lung
tissu
assay
sarscov
lung
titer
remain
mice
per
group
bodi
weight
morbid
mortal
measur
daili
day
second
anim
studi
measur
sarscov
neutral
antibodi
titer
total
group
week
old
femal
balbc
mice
mice
per
group
immun
im
vehicl
g
g
sar
vlp
vaccin
without
aluminum
hydroxid
adjuv
day
day
anim
bled
day
measur
neutral
antibodi
titer
anim
undetect
level
sarscov
neutral
antibodi
titer
day
sarscov
urbani
strain
obtain
center
diseas
control
prevent
atlanta
ga
routin
pass
cell
sarscov
lethal
strain
deriv
mous
adapt
urbani
strain
mous
lung
weigh
homogen
mem
minimum
essenti
medium
lung
homogen
centrifug
g
min
fold
serial
dilut
supernat
assay
triplic
infecti
viru
plaqu
assay
use
viru
titer
measur
ccid
g
tissu
calcul
use
reedmuench
method
titer
ccid
g
tissu
minimum
detect
limit
assay
l
aliquot
serum
ad
l
mem
gml
gentamicin
mix
serial
dilut
achiev
dilut
roundbottom
plate
sarscov
urbani
strain
stock
dilut
mem
ccid
per
l
l
dilut
viru
ad
well
plate
vibrat
approxim
min
incub
h
c
l
virusserum
mixtur
well
transfer
well
plate
contain
subconflu
cell
l
mem
fetal
bovin
serum
fb
plate
seal
tape
incub
day
c
co
score
presenc
absenc
viru
microscop
base
cytopath
effect
cpe
neutral
titer
calcul
invers
greatest
dilut
serum
cpe
detect
assay
perform
duplic
serum
titer
lowest
dilut
test
assay
anim
studi
conduct
accord
approv
institut
anim
care
use
committe
full
length
recombin
sar
protein
produc
baculoviru
insect
cell
express
system
fig
sar
protein
isol
infect
cell
solubl
nonion
lung
sarscov
titer
day
day
post
challeng
viru
titer
calcul
lung
tissu
result
express
mean
titer
sem
statist
signific
vehicl
vaccin
group
determin
student
test
p
deterg
purifi
column
chromatographi
purifi
full
length
sar
protein
appar
molecular
weight
kda
sdspage
fig
purifi
sar
protein
form
nm
diamet
particl
consist
multipl
protein
molecul
observ
dynam
light
scatter
electron
microscopi
data
shown
attempt
produc
wild
type
sar
vlp
homolog
sar
e
protein
insect
cell
process
ineffici
vlp
incorpor
protein
could
detect
western
blot
e
protein
band
observ
coomassi
blue
stain
gel
data
shown
probabl
due
lack
effici
matrix
core
protein
need
vlp
format
influenza
matrix
protein
especi
avian
influenza
shown
support
product
high
yield
influenza
vlp
even
hemagglutinin
neuraminidas
heterolog
influenza
strain
result
studi
decid
explor
possibl
form
chimer
vlp
contain
sar
protein
influenza
matrix
protein
maxim
interact
sar
influenza
replac
wild
type
sar
protein
transmembran
carboxyl
terminu
tmct
influenza
viru
hemagglutinin
tmct
construct
tandem
transfer
vector
chimer
vlp
product
shown
fig
chimer
vlp
produc
high
level
insect
cell
purifi
infect
cultur
medium
purifi
vlp
produc
intens
sar
influenza
protein
band
coomassi
blue
stain
gel
respect
puriti
measur
scan
densitometri
fig
two
addit
protein
band
present
vlp
identifi
baculoviru
envelop
protein
insect
cell
skeleton
protein
western
blot
data
shown
two
protein
detect
previous
influenza
vlp
produc
insect
cell
tubulin
like
resid
insid
vlp
sinc
may
work
togeth
actin
facilit
baculoviru
vlp
transit
cell
surfac
glycoprotein
like
embed
vlp
envelop
addit
cell
cultur
purif
develop
may
help
reduc
level
baculoviru
insect
cell
protein
sar
vlp
averag
diamet
chimer
vlp
nm
measur
dynam
light
scatter
vlp
contain
spheric
envelop
particl
coronalik
spike
structur
outer
rim
determin
electron
microscopi
em
fig
size
morpholog
vlp
close
resembl
previous
publish
sarscov
structur
immunoem
use
antisar
protein
primari
antibodi
nm
gold
particl
label
secondari
antibodi
show
multipl
protein
locat
surfac
spheric
vlp
fig
immunogen
protect
efficaci
sar
protein
chimer
vlp
vaccin
test
mous
lethal
challeng
model
mice
intramuscularli
im
intranas
immun
vehicl
g
g
sar
protein
vlp
without
aluminum
hydroxid
adjuv
day
anim
challeng
sarscov
lethal
strain
day
mice
vehicl
control
group
die
day
post
challeng
fig
im
immun
group
g
purifi
sar
protein
without
alum
protect
mice
death
fig
im
group
mice
protect
death
fig
b
mice
immun
g
g
purifi
sar
protein
without
alum
lost
bodi
weight
respect
fulli
recov
fig
vlp
group
alum
group
show
sign
weight
loss
fig
lung
viru
titer
day
post
challeng
appear
correl
surviv
data
fig
without
adjuv
g
sar
protein
fail
significantli
reduc
lung
viru
titer
g
sar
protein
reduc
viru
titer
log
g
sar
vlp
reduc
viru
titer
log
g
sar
vlp
reduc
viru
titer
detect
limit
likewis
group
contain
sar
protein
alum
lung
viru
titer
reduc
detect
limit
data
indic
low
g
im
administ
sar
vlp
vaccin
without
adjuv
fulli
protect
mice
death
weight
loss
lethal
viru
challeng
im
administ
sar
protein
vaccin
fulli
protect
mice
coadminist
alum
adjuv
immun
adjuv
use
g
g
sar
protein
fail
protect
mice
lethal
challeng
result
death
vehicl
control
group
wherea
mice
immun
g
g
sar
vlp
surviv
viru
challeng
fig
b
net
weight
loss
vlp
vaccin
group
high
anim
complet
recov
fig
also
sar
protein
fail
reduc
lung
viru
titer
g
g
vlp
vaccin
group
lung
viru
titer
reduc
log
respect
fig
data
show
without
effect
adjuv
sar
protein
fail
protect
administ
vlp
vaccin
without
adjuv
protect
mice
death
similar
vaccin
given
im
howev
lung
viru
titer
vlp
vaccin
group
log
higher
correspond
im
group
immun
anim
suffer
minor
weight
loss
data
im
lethal
challeng
studi
indic
sar
protein
vaccin
requir
effect
adjuv
protect
vaccin
im
rout
administr
work
better
reduc
lung
viru
titer
one
possibl
explan
local
immun
mainli
induc
upper
respiratori
tract
immun
lower
respiratori
tract
sarscov
replic
immun
fulli
establish
time
challeng
wherea
im
immun
broader
system
humor
immun
develop
offer
better
protect
sarscov
challeng
respiratori
tract
im
immun
may
also
induc
higher
neutral
antibodi
titer
help
reduc
lung
viru
titer
measur
humor
neutral
antibodi
respons
mice
immun
im
vehicl
g
g
sar
protein
chimer
sar
vlp
without
aluminum
hydroxid
day
mice
bled
day
sera
sampl
assay
neutral
antibodi
sarscov
fig
sar
protein
sar
vlp
need
two
vaccin
elicit
neutral
antibodi
titer
sar
vaccin
requir
alum
adjuv
induc
neutral
antibodi
titer
base
line
wherea
g
g
vlp
vaccin
without
alum
induc
neutral
antibodi
titer
respect
result
directli
correl
surviv
rate
post
challeng
lung
viru
titer
shown
fig
sar
vaccin
alum
sar
vlp
vaccin
group
neutral
antibodi
geometri
mean
titer
rang
statist
differ
alum
group
show
trend
higher
neutral
antibodi
titer
day
vlp
alum
one
explan
may
protein
absorb
alum
effici
vlp
slow
releas
alum
result
prolong
elev
antibodi
respons
day
paper
report
novel
method
produc
chimer
sar
vlp
contain
spike
protein
sar
matrix
protein
influenza
viru
use
baculoviru
insect
cell
express
system
obtain
level
mg
content
sar
vlp
per
liter
cell
cultur
shake
flask
upon
cell
cultur
optim
stir
tank
reactor
high
cell
densiti
fedbatch
medium
exchang
purif
develop
yield
expect
increas
sever
fold
studi
immunogen
protect
efficaci
sar
protein
vaccin
sar
vlp
vaccin
mice
lethal
challeng
model
vlp
vaccin
without
adjuv
protect
immun
mice
death
given
im
reduc
lung
viru
titer
undetect
level
elicit
serum
neutral
antibodi
titer
hand
protein
vaccin
requir
alum
adjuv
effect
protect
mice
lethal
challeng
reduc
lung
viru
titer
elicit
neutral
antibodi
data
suggest
sar
vaccin
alum
sar
vlp
vaccin
good
candid
protect
sarscov
infect
administ
im
recombin
vlp
vaccin
attract
approach
vaccin
develop
past
decad
vlp
contain
viral
genom
therefor
replic
human
revert
pathogen
form
characterist
make
vlp
safer
vaccin
recipi
also
safer
vaccin
manufactur
inactiv
live
attenu
viral
vaccin
especi
danger
viru
sarscov
caus
high
morbid
death
repetit
antigen
pattern
repres
surfac
vlp
make
easier
recogn
antigen
present
cell
subunit
vaccin
therefor
abl
induc
stronger
broader
humor
cellular
immun
respons
three
vlp
vaccin
approv
human
use
hepat
b
vaccin
two
hpv
vaccin
three
compos
singl
protein
particl
without
lipid
bilay
envelop
addit
one
commerci
hpv
vaccin
cervarix
produc
baculoviru
insect
cell
express
system
complex
version
vlp
influenza
vlp
contain
hemagglutinin
neuraminidas
protein
lipid
bilay
envelop
current
evalu
phase
ii
human
clinic
trial
novavax
inc
vlp
vaccin
approv
late
stage
clinic
develop
partial
vlp
usual
difficult
produc
high
level
due
lack
effici
viral
core
protein
report
show
influenza
matrix
protein
potenti
becom
univers
core
protein
support
vlp
product
virus
coincid
form
vlp
sar
protein
sarscov
influenza
viru
share
mani
common
featur
rna
genom
nm
diamet
spheric
particl
major
surfac
spike
glycoprotein
ha
form
trimer
spike
glycoprotein
contain
globular
head
domain
stem
region
replac
sar
tmct
ha
tmct
may
help
maxim
nativ
interact
core
protein
surfac
antigen
promot
vlp
format
secret
use
influenza
core
protein
form
vlp
virus
promis
approach
explor
futur
besid
potenti
yield
increas
influenza
contain
chimer
vlp
quickli
activ
specif
memori
cell
sinc
human
popul
infect
multipl
time
influenza
viru
lifetim
activ
specif
cell
stimul
sar
antigen
specif
b
cell
differenti
antibodi
secret
sar
chimer
vlp
vaccin
manufactur
procedur
influenza
vlp
vaccin
success
test
phase
phase
ii
clinic
studi
two
product
share
common
infrastructur
equip
suppli
medium
resin
filter
etc
util
sever
ident
standard
oper
procedur
unfortun
case
anoth
sar
pandem
countri
region
exist
influenza
vlp
vaccin
manufactur
capac
abil
quickli
switch
sar
vaccin
product
facil
like
switch
anoth
season
flu
strain
sar
vlp
vaccin
produc
influenza
vlp
vaccin
manufactur
facil
within
short
week
period
pandem
viru
identifi
sequenc
sooner
urbanilik
strain
reoccur
multius
facil
season
flu
pandem
flu
sar
may
desir
mani
countri
anoth
sar
pandem
border
countri
may
close
restrict
vaccin
enter
thu
pandem
vaccin
manufactur
capac
within
one
border
may
critic
protect
citizen
infect
